Ajay Kumar Gopal MD

Hematologic Oncology

Professor, Medicine, University of Washington School of Medicine: Member, Fred Hutchinson Cancer Research Center; Clinical Research Director- Hematologic Malignancies- Seattle Cancer Care Alliance

Join to View Full Profile

Seattle Cancer Care Alliance (UW/FHCRC)825 Eastlake Avenue EastSeattle, WA 98109
Phone+1 206-606-1000

Summary

Dr. Ajay Gopal is an oncologist in Seattle, WA and is affiliated with multiple hospitals in the area, including University of Washington Medical Center and Seattle Cancer Care Alliance. He received his medical degree from Emory University School of Medicine and has been in practice 24 years. He specializes in hematologic oncology and is experienced in hematologic oncology, Hodgkin’s lymphoma, non-Hodgkin’s Lymphoma, CLL, transplant, and cellular therapy.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1997 - 2000
Duke University HospitalResidency, Internal Medicine, 1993 - 1996
Emory University School of MedicineClass of 1993

Certifications & Licensure

WA State Medical License 1997 - 2026
NC State Medical License 1996 - 1998
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Start of enrollment: 2003 Aug 01
Completed
Phase 2
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 1999 Feb 01
Completed
Phase 2
Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 1999 Oct 01
Completed
Phase 2
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2005 Jan 01
Completed
Phase 1
A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma Start of enrollment: 2009 Nov 01
Terminated
Phase 2
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Start of enrollment: 2009 Feb 01
Terminated
Phase 1
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Start of enrollment: 2010 Aug 01
Completed
Phase 2
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma Start of enrollment: 2010 Sep 01
Completed
Phase 1, Phase 2
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma Start of enrollment: 2011 Nov 16
Terminated
Phase 2
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies Start of enrollment: 1999 Sep 01
Terminated
Phase 1
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma Start of enrollment: 2013 Mar 20
ACTIVE_NOT_RECRUITING
PHASE2
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies Start of enrollment: 2013 Oct 09
Completed
Phase 1, Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies Start of enrollment: 2014 Mar 13
Completed
Phase 1, Phase 2
Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
COMPLETED
PHASE2
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2014 Oct 10
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies Start of enrollment: 2017 Feb 08
Terminated
Phase 1, Phase 2
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL Start of enrollment: 2017 Apr 24
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

Digital pathology and image analysis of p53 biomarker in lymphomas using two algorithms: correlation with genotype and visual inspection.
Anisha Naik, Aarti Kanzaria, Xueyan Chen, Navneet Kaur, Chia-Chen Joyce Ho
Journal of Clinical Pathology. 2025-10-17
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.
Ryan C Lynch, Ryan D Cassaday, Stephen D Smith, Andrew J Cowan, Edus H Warren
British Journal of Haematology. 2025-10-01
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma.
Chaitra Ujjani, Hongkun Wang, Catherine Broome, Ajay K Gopal, Stephen D Smith
Clinical Lymphoma, Myeloma & Leukemia. 2025-10-01

Journal Articles

Translating Anti-CD19 CAR T-cell Therapy into Clinical Practice for relapsed/refractory Diffuse Large B-cell Lymphoma
Mazyar Shadman, Ajay K Gopal, Victor A Chow, Blood

Abstracts/Posters

AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ibrutinib Selects for Cells with Elevated Reactive Oxygen Species and Downregulated Phosphatases
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Diffuse Large B-Cell Lymphoma Is Infiltrated with Functional CD8+ T-Cells Lacking the Hallmarks of Exhaustion
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Indolent Lymphomas: The Marathon Has a New Course
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell TherapyClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Dr. Ajay Gopal Named Stephen H. Petersdorf Endowed Chair in Cancer Care at UW MedicineJanuary 26th, 2023
DLBCL: PFS but No OS Benefit with Polatuzumab-Vedotin Add-OnDecember 17th, 2021
Ibrutinib Add-on 'Almost Certainly' Saves Lives in DLBCLNovember 4th, 2021
Join now to see all

Grant Support

Radioimmunotherapy For LymphomaNational Cancer Institute2011
Radiolabeled Antibody Therapy Of B-Cell LymphomaNational Cancer Institute2005–2009
Proapoptotic Therapy For B-Cell NON Hodgkin'S LymphomaNational Cancer Institute2006–2007
Optimizing Radioimmunotherapy For NON Hodgkin'S LymphomaNational Cancer Institute2000–2005